Shares of FibroGen, Inc (NASDAQ:FGEN) hit a new 52-week high during mid-day trading on Tuesday after Citigroup raised their price target on the stock to $65.00. Citigroup currently has a top pick rating on the stock. FibroGen traded as high as $49.10 and last traded at $49.00, with a volume of 6,880,330 shares trading hands. The stock had previously closed at $33.40.

A number of other brokerages also recently issued reports on FGEN. Zacks Investment Research downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a report on Monday, May 8th. BidaskClub raised shares of FibroGen from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Jefferies Group LLC reaffirmed a “buy” rating and set a $75.00 price target on shares of FibroGen in a report on Tuesday. Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price target on the stock. in a report on Friday, July 21st. Finally, Stifel Nicolaus raised their price target on shares of FibroGen from $38.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. FibroGen presently has a consensus rating of “Buy” and a consensus price target of $56.86.

In related news, VP Pat Cotroneo sold 2,891 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $28.75, for a total value of $83,116.25. Following the transaction, the vice president now owns 163,366 shares of the company’s stock, valued at $4,696,772.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Toshinari Tamura sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $28.89, for a total transaction of $866,700.00. Following the completion of the transaction, the director now directly owns 60,000 shares in the company, valued at approximately $1,733,400. The disclosure for this sale can be found here. In the last three months, insiders sold 404,974 shares of company stock worth $12,515,438. 14.90% of the stock is currently owned by insiders.

Several institutional investors have recently bought and sold shares of FGEN. Vanguard Group Inc. increased its position in FibroGen by 8.4% in the first quarter. Vanguard Group Inc. now owns 5,047,018 shares of the biopharmaceutical company’s stock worth $124,409,000 after buying an additional 392,778 shares during the last quarter. BlackRock Inc. increased its position in FibroGen by 29,724.1% in the first quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock worth $109,811,000 after buying an additional 4,439,882 shares during the last quarter. FMR LLC increased its position in FibroGen by 10.5% in the first quarter. FMR LLC now owns 1,694,574 shares of the biopharmaceutical company’s stock worth $41,771,000 after buying an additional 161,143 shares during the last quarter. State Street Corp increased its position in FibroGen by 11.1% in the first quarter. State Street Corp now owns 1,514,465 shares of the biopharmaceutical company’s stock worth $37,336,000 after buying an additional 150,807 shares during the last quarter. Finally, Janus Capital Management LLC increased its position in FibroGen by 1.1% in the first quarter. Janus Capital Management LLC now owns 1,363,657 shares of the biopharmaceutical company’s stock worth $33,613,000 after buying an additional 14,882 shares during the last quarter. 43.45% of the stock is currently owned by institutional investors.

The firm’s market cap is $3.46 billion. The stock has a 50-day moving average price of $33.32 and a 200-day moving average price of $27.67.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.01. The firm had revenue of $29 million during the quarter, compared to analysts’ expectations of $34.80 million. FibroGen had a negative net margin of 37.60% and a negative return on equity of 36.41%. On average, analysts expect that FibroGen, Inc will post ($1.85) EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was published by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/09/fibrogen-inc-nasdaqfgen-reaches-new-1-year-high-after-analyst-upgrade.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.